Weber JS - Search Results

1

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. Hersh EM, et al. Among authors: weber js. Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16. Invest New Drugs. 2011. PMID: 20082117 Clinical Trial.

2

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.

Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH. Margolin K, et al. Invest New Drugs. 2001;19(4):335-40. doi: 10.1023/a:1010626230081. Invest New Drugs. 2001. PMID: 11561695 Clinical Trial.

3

Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery.

Yu C, Chen JC, Apuzzo ML, O'Day S, Giannotta SL, Weber JS, Petrovich Z. Yu C, et al. Among authors: weber js. Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1277-87. doi: 10.1016/s0360-3016(01)02772-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 11955740

4

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Sanderson K, et al. J Clin Oncol. 2005 Feb 1;23(4):741-50. doi: 10.1200/JCO.2005.01.128. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613700

5

Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.

Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J. Liu D, et al. Clin Cancer Res. 2005 Feb 1;11(3):1237-46. Clin Cancer Res. 2005. PMID: 15709194

6

A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.

Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R. Lewis KD, et al. Cancer Invest. 2005;23(4):303-8. doi: 10.1081/cnv-58832. Cancer Invest. 2005. PMID: 16100942 Clinical Trial.

7

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. Lewis KD, et al. Among authors: weber js. Invest New Drugs. 2006 Jan;24(1):89-94. doi: 10.1007/s10637-005-4544-y. Invest New Drugs. 2006. PMID: 16379038 Clinical Trial.

8

Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.

Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Weber J, et al. J Immunother. 2008 Feb-Mar;31(2):215-23. doi: 10.1097/CJI.0b013e3181611420. J Immunother. 2008. PMID: 18481391 Clinical Trial.

9

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Weber JS, et al. J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018089 Clinical Trial.

10

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.

Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S. Weber JS, et al. Cancer. 2009 Sep 1;115(17):3944-54. doi: 10.1002/cncr.24473. Cancer. 2009. PMID: 19536884 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page